Related Experiment Videos
[Antibiotherapy as first choice in infectious meningitis]
R Cohen1, F de La Rocque, E Varon
1Service de microbiologie, CHI Créteil, France.
Abstract:
The choice of antibiotics in bacterial meningitis must integrate several parameters. i) The bacterial epidemiology of community acquired meningitis: Haemophilus influenzae (Hi) Neisseria meningitidis (Nm), Streptococcus pneumoniae (Sp) represents more than 95% of cases; ii) The increase of antibiotic bacterial resistance, particularly preoccupying for Sp; iii) The microbiological properties and pharmacokinetics of antibiotics, especially their penetration in CSF: the concentrations achieved must be several times higher than the MBC. In fact, CSF is not favourable to the antibiotic activity; iv) The results of clinical comparative trials; v) The contribution of animal models to the knowledge of meningitis physiopathology. Third generation cephalosporins (cefotaxime, ceftriaxone) satisfy this objective for Hi, Nm, and penicillin sensitive strains of Sp. For penicillin resistant Sp, no treatment can achieve antibiotic CSF concentrations higher than ten times the MBC. An increase in dosage of cephalosporins, the use of an other regimen (Vancomycin or imipenem) and antibiotic association (rifamycin, fosfomycin) are needed.
Insights
Choosing antibiotics for bacterial meningitis requires considering bacterial resistance and drug penetration into cerebrospinal fluid (CSF). Third-generation cephalosporins are effective for most common pathogens, but resistant Streptococcus pneumoniae strains necessitate alternative treatments.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Bacterial meningitis treatment selection hinges on pathogen epidemiology, antibiotic resistance, and pharmacokinetic properties.
- Key pathogens include Haemophilus influenzae (Hi), Neisseria meningitidis (Nm), and Streptococcus pneumoniae (Sp), accounting for over 95% of community-acquired cases.
- Increasing antibiotic resistance, especially in Streptococcus pneumoniae, complicates treatment strategies.
Framework:
- Antibiotic efficacy in meningitis depends on achieving concentrations significantly higher than the Minimum Bactericidal Concentration (MBC) within the cerebrospinal fluid (CSF).
- Cerebrospinal fluid (CSF) presents a challenging environment for antibiotic activity.
- Clinical trials and animal models are crucial for understanding meningitis pathophysiology and evaluating treatment effectiveness.
Implementation:
- Third-generation cephalosporins (cefotaxime, ceftriaxone) are recommended for Haemophilus influenzae (Hi), Neisseria meningitidis (Nm), and penicillin-susceptible Streptococcus pneumoniae (Sp).
- Penicillin-resistant Streptococcus pneumoniae (Sp) strains pose a therapeutic challenge, often failing to reach adequate antibiotic concentrations in CSF.
- Management of resistant strains may involve increased cephalosporin dosages, alternative agents like Vancomycin or Imipenem, or combination therapy with agents such as Rifamycin or Fosfomycin.
Implications:
- Optimizing antibiotic selection is critical for improving patient outcomes in bacterial meningitis.
- Addressing antibiotic resistance in Streptococcus pneumoniae is a priority for effective meningitis treatment.
- Further research into novel therapeutic strategies and drug combinations is warranted for challenging meningitis cases.